| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 283.7 | 249.3 |
| Gross profit | 160.4 | 134.3 |
| Profit before tax | -7.7 | -25.1 |
| Net income | -7.1 | -21.2 |
| EPS (diluted, $ a share) | $-0.10 | $-0.31 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +13.8% |
|---|---|
| Gross margin | 56.5% |
| Operating margin | -0.8% |
10-Q filed with the SEC, NASDAQ: TNDM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Tandem Diabetes Care Inc: key numbers
- Share price
- $18.48Close, Nov 16
- Market cap
- $1.29B
- Shares outstanding
- 69.79MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Tandem Diabetes Care Inc
All →Tandem Diabetes Care Regulatory Approval
Tandem Diabetes Care received FDA 510(k) clearance for Tandem Mobi, the world's first and only tubeless automated insulin delivery system with up to 7 days of wear. The clearance allows the pump to offer both tubed and tubeless infusion options, with a full commercial launch planned for the first half of 2027.
Tandem Diabetes Care Financial Results
Tandem Diabetes Care reported Q3 2026 worldwide sales of $283.7 million, a 14% increase year-over-year, driven by strong international growth and expanded pump shipments. The company significantly narrowed its net loss to $7.1 million and reaffirmed its full-year 2026 sales guidance of $1.065 billion to $1.085 billion.
- Term
- Q3 2026
“Tandem’s third-quarter performance demonstrates that our strategy is delivering results. We are expanding access to Tandem’s life-changing technology, strengthening our business model, advancing our pipeline and driving greater operating efficiency, creating a stronger foundation for sustainable, profitable growth.”
John Sheridan, president and chief executive officer
Tandem Diabetes Care Insider Christopher J. Twomey Sells $32.6K of Stock
Christopher J. Twomey sold 1,700 shares of Tandem Diabetes Care Inc at $19.15 a share, worth $32.6K in total on Oct 27, 2026. Shares held after the trade: 24,434 (-6.5%).
- Value
- $32.6K
- Shares
- 1,700
- Price
- $19.15
- Holding change
- -6.5%
- Trade date
- Oct 27, 2026